Asia Rheumatoid Arthritis Clinical Trial Analysis, Rheumatoid Arthritis Product Pipeline - Ken Research

1
New Therapies to Bolster Asia-Pacifics
Rheumatoid Arthritis Market - Ken Research
2
Rheumatoid arthritis (RA) is a chronic,
progressive and incurable auto-immune disease
that majorly affects the joints in a human body.
It is identified by synovial inflammation and
gradual bone erosion over the years. The major
symptoms are stiffness, pain in hands and feet
and obstruct a patients mobility. Lack of
medical help will result in joint destruction and
disability. Any patient suffering from rheumatoid
arthritis requires continuous treatment that is
relatively very expensive. Therefore, rheumatoid
arthritis therapeutic market is highly
competitive due to increasing number of new drug
approvals. Competition is fierce in the
therapeutic market among TNF-a inhibitors for
patients who are refractory to traditional
disease-modifying anti-rheumatic drugs
(DMARD). Majority of the rheumatoid arthritis
patients do not respond when treated with TNF-a
inhibitors. Therefore, small-molecule DMARDs such
as the Janus kinase (JAK) inhibitor and Xeljanz
(tofacitinib) replace the ineffective TNF-a
inhibitors. Xeljanz is very effective because it
reduces the risk of developing cardiac diseases
such as heart attack and stroke in patients.
Xeljanz is an orally administered small-molecule
drug which is used as a second-line treatment for
rheumatoid arthritis patients who do not respond
to methotrexate, and as a third-line therapy for
rheumatoid arthritis patients who do not respond
to biologics.
3
According to the study Rheumatoid Arthritis
Therapeutics in Asia-Pacific Markets to
2023-Novel JAK and IL-6 Receptor Inhibitors to
Stimulate Moderate Growth Despite Launch of
Biosimilars of Blockbuster Anti-TNFs, in
Asia-Pacific region, there is a need to improve
safety in the therapeutic category. Elevated
rates of infection were observed due to frequent
consequences of the immune-suppression involved
in treatments. Therefore, biological therapies
are not recommended to patients who are
susceptible to any infection. There is a need
to create biologics with more convenient and less
invasive drug-delivery methods because the
existing therapies for rheumatoid arthritis are
administered subcutaneously or intravenously.
Such drug delivery methods in rheumatoid
arthritis patients are frequently associated with
pain, rash, and allergic reactions at the
injection or infusion site, in the case of
infusion, flu-like illness, fever, chills,
nausea, and headache. There is a need to develop
convenient and safe drug administration
procedures for rheumatoid arthritis patients.
4
Advanced medical technology has witnessed great
changes in the field of diagnostic technology to
strengthen the performance of rheumatoid
arthritis drug manufacturers in Asia-Pacific
region. The new products in the Asia-Pacific
rheumatoid arthritis market are Sirukumab, an
antiIL6 human mAb Peficitinib, Upadacitinib and
Filgotinib, which are JAK1 inhibitors
Olokizumab, an antiIL6 humanized IgG4 mAb and
RCT18, a recombinant human Blymphocyte
stimulating factor (BLyS) receptor antibody
fusion protein. With the recently approved
rheumatoid arthritis therapies along with new
therapies are sure to drive the rheumatoid
arthritis therapeutics market in Asia-Pacific.
The promising pipeline companies are Johnson
Johnson (JJ), GlaxoSmithKline (GSK)'s sirukumab,
and Galapagos's filgotinib. The leading players
in rheumatoid arthritis therapeutics market are
AbbVie, Amgen, Amgen, Daiichi Sankyo, Biogen
Idec, Genentech, Bristol-Myers Squibb, Eli Lilly,
Johnson Johnson, Merck, Pfizer, Regeneron,
Sanofi, Roche and UCB.
5
India, Australia, China, South Korea and Japan
are the leading consumers in Asia-Pacific (APAC)
rheumatoid arthritis therapeutics market. Japan
accounted for a majority share of the market,
followed by China, Australia, India and South
Korea. The introduction of biologic disease
modifying antirheumatic drugs (DMARD) has helped
in the growth of the rheumatoid arthritis (RA)
market in Asia-Pacific tremendously over the last
two decades. This growth is expected to continue
at a moderate pace in the next few years.
6
To know more, click on the link
below https//www.kenresearch.com/healthcare/gene
ral-healthcare/rheumatoid-arthritis-therapeutics-i
n-asia-pacific-markets-to-2023-novel-jak-and-il-6-
receptor-inhibitors-to-stimulate-moderate-growth-d
espite-launch-of-biosimilars-of-blockbuster-anti-t
nfs/149110-91.html Related Reports https//www.k
enresearch.com/healthcare/general-healthcare/osteo
arthritis-pipeline-review/143930-91.html https//
www.kenresearch.com/healthcare/pharmaceuticals/ost
eoarthritis-pipeline-review-h2-2017/142124-91.html
Contact Us Ken Research Ankur Gupta, Head
Marketing Communications sales_at_kenresearch.com 0
124-4230204